Dynamics of antibody titers to SARS-CoV-2 and clinical outcomes after sotrovimab pre-exposure prophylaxis early after allogeneic hematopoietic stem cell transplantation - Summary - MDSpire

Dynamics of antibody titers to SARS-CoV-2 and clinical outcomes after sotrovimab pre-exposure prophylaxis early after allogeneic hematopoietic stem cell transplantation

  • By

  • Gioele Capoferri

  • Carla Simone Walti

  • Pascal Urwyler

  • Silvio Ragozzino

  • Jakob R. Passweg

  • Jörg Halter

  • Manuel Battegay

  • Veronika Baettig

  • Maja Weisser

  • Brice Arnold

  • Benedict Morin

  • Yukino Guetlin

  • Diana Albertos Torres

  • Güliz Tuba Barut

  • Volker Thiel

  • Adrian Egli

  • Beatrice Drexler

  • Nina Khanna

  • February 16, 2023

  • 0 min

Share

Objective:

To generate real-world data on the dynamics of neutralization activity and total immunoglobulin levels against SARS-CoV-2, safety, and breakthrough infections in alloHCT recipients receiving sotrovimab as PrEP, specifically focusing on antibody responses and infection rates.

Key Findings:
  • 36 out of 41 patients were included in the study.
  • Median time to sotrovimab administration was 29 days post-alloHCT.
  • Anti-S/RBD total Ig levels increased significantly after sotrovimab, with 86.1% of patients above detection limits by day 60.
  • Neutralizing antibody titers peaked at day 7, with significant increases observed across variants.
  • Breakthrough infections occurred in 19.4% of patients, with most being asymptomatic, indicating a need for ongoing monitoring.
Interpretation:

Sotrovimab administration in newly transplanted alloHCT recipients led to significant increases in antibody levels and neutralizing activity, although breakthrough infections were observed.

Limitations:
  • Small sample size may limit generalizability and the robustness of the findings.
  • Lack of long-term follow-up data beyond 90 days.
Conclusion:

Sotrovimab appears to be effective in enhancing antibody responses in alloHCT recipients, although breakthrough infections can still occur, highlighting the need for continued vigilance.

Original Source(s)

Dynamics of antibody titers to SARS-CoV-2 and clinical outcomes after sotrovimab pre-exposure prophylaxis early after allogeneic hematopoietic stem cell transplantation

  • by Gioele Capoferri, Carla Simone Walti, Pascal Urwyler, Silvio Ragozzino, Jakob R. Passweg, Jörg Halter, Manuel Battegay, Veronika Baettig, Maja Weisser, Brice Arnold, Benedict Morin, Yukino Guetlin, Diana Albertos Torres, Güliz Tuba Barut, Volker Thiel, Adrian Egli, Beatrice Drexler, Nina Khanna

  • February 16, 2023

Related Content

Viral infections and risk, in Wine and Medicine

Sample average treatment effect on the treated (SATT) analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity and survival in patients with multiple myeloma

Journal of the Pediatric Infectious Diseases Society and the Journal of Infectious Diseases Collaboration: The First Fruits From a New Tree